Managing Blood Bank Compatibility

職業

カテゴリ

ラボツール

1. Clinical scenario — Routine pre-surgical, active bleeding, massive transfusion, prenatal, chronic transfusion patient, or transplant? Default: routine pre-surgical.
2. Patient history — Prior transfusion reactions, known antibodies, previous pregnancies, transplant status? Default: no history; flag [VERIFY].
3. Current sample — Specimen type (EDTA tube), time of collection, two-identifier verification performed? Default: EDTA, < 72 hours.
4. Urgency — Routine, urgent (1-2 hours), emergent (immediate release)? Default: routine.
5. Product type needed — RBCs, platelets, plasma, cryoprecipitate, or granulocytes? Default: RBCs.
6. Special requirements — Irradiated, CMV-negative, HbS-negative, washed, volume-reduced, extended antigen-matched? Default: none.
7. Number of units — How many units anticipated? Default: 2 units RBC type and screen.

Documents to Request

• Current type and screen specimen with two-identifier label verification
• Patient transfusion history (internal and external records)
• Previous antibody identification records
• Prenatal antibody records and paternal antigen typing if applicable
• Clinical notes (diagnosis, surgical plan, estimated blood loss)
• Medication list (daratumumab, anti-CD38 interference with crossmatch)
• Prior transfusion reaction investigation reports

Step 1: ABO/Rh Typing and Confirmation

Perform ABO and Rh(D) typing following AABB Standards:

Forward (cell) typing:

Reverse (serum) typing:

• Discrepancy resolution: If forward and reverse do not agree, hold and investigate: cold autoantibodies, missing antibodies (hypogammaglobulinemia, age < 4 months), subgroups (A2 with anti-A1), or recent transfusion of non-type-specific products.
• Rh(D) weak D testing: Per AABB/CAP recommendations, test for weak D in donors (always) and patients (institutional policy; recent guidance supports genotyping for weak D types 1, 2, 3 which can safely receive Rh-positive blood).

Step 2: Antibody Screening

Perform antibody screen using FDA-licensed screening cells (2-3 cell panel) per AABB Standards:

• Methods: Immediate spin (IS), 37°C incubation, indirect antiglobulin test (IAT) using PEG, LISS, or solid-phase technology.
• Interpretation:
  • All cells negative at all phases: Screen negative, proceed to electronic crossmatch (if criteria met) or serologic crossmatch.
  • One or more cells reactive: Proceed to antibody identification panel.

Electronic crossmatch eligibility (per AABB Standards 5.16.3):

• Two concordant ABO/Rh typings on file (current and historical)
• Negative antibody screen on current specimen
• Validated computer system with logic to prevent ABO-incompatible issuance

Step 3: Antibody Identification

When the antibody screen is positive, perform a full panel workup:

1. Panel testing: Run an 11-16 cell identification panel at IS, 37°C, and IAT phases.
2. Rule-out process: Eliminate antigens present on non-reactive cells. An antibody can be ruled out when at least two panel cells homozygous for the antigen are non-reactive (per rule of three for statistical validity).
3. Common clinically significant alloantibodies:

4. Additional techniques for complex cases:
   • Enzyme treatment (ficin, papain): Enhances Rh, Kidd, Lewis; destroys Duffy, MNS
   • Adsorption (auto or allo): Warm autoantibody removal to unmask underlying alloantibodies
   • Elution: Identify antibody specificity from coated red cells
   • DTT treatment: Denature IgM antibodies or Kell antigens

Step 4: Crossmatch and Product Selection

Select compatible products based on antibody identification:

• Antigen-negative unit selection: Screen donor units for absence of the corresponding antigen. Confirm antigen-negative status before issuing.
• Crossmatch: Perform serologic crossmatch (IAT) for patients with clinically significant antibodies. Electronic crossmatch permitted only when screen is negative and eligibility criteria are met.
• Extended antigen matching: For chronically transfused patients (sickle cell disease, thalassemia), match for C, E, and K at minimum per AABB recommendations. Consider extended Rh and Kell matching (C, c, E, e, K) prophylactically.
• Emergency release: When life-threatening bleeding cannot wait for crossmatch, issue uncrossmatched O-negative (or O-positive for males) RBCs. Document emergency release per institutional protocol. Switch to type-specific as soon as possible.

Step 5: Documentation and Release

• Record all testing results, interpretations, and product selection rationale.
• Tag each unit with patient identifiers, ABO/Rh compatibility statement, special requirements, and expiration.
• Final bedside verification: Two-identifier patient check, product label verification, and ABO compatibility confirmation immediately prior to transfusion.
• Document time of release, releasing technologist identity, and receiving nurse/provider.
• For massive transfusion protocol (MTP) activation, document MTP start time, product ratios issued (target 1:1:1 RBC:FFP:platelet), and communication log with clinical team.

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Are ABO forward and reverse typing concordant, and if not, is the discrepancy investigation documented?
2. Is the antibody identification supported by rule-out of at least two homozygous-positive non-reactive cells per antibody specificity?
3. Are antigen-negative units confirmed negative before crossmatch?
4. Is the crossmatch method appropriate for the patient's antibody status (electronic vs. serologic IAT)?
5. Is emergency release documented with proper rationale and follow-up completion plan?

Quality Audit

• Two-identifier sample verification documented at collection and receipt
• ABO forward and reverse typing concordant or discrepancy investigated
• Rh(D) typing complete with weak D testing per institutional policy
• Antibody screen performed at IS, 37°C, and IAT phases
• Antibody identification uses rule of three for statistical validity
• Clinically significant antibodies distinguished from insignificant cold agglutinins
• Antigen-negative units confirmed before crossmatch
• Electronic crossmatch criteria verified when applicable
• Emergency release protocol followed with documentation
• Transfusion reaction investigation protocol available and referenced
• Chronically transfused patients receive prophylactic antigen matching (C, E, K minimum)
• All testing results recorded with technologist identity and timestamps
• AABB Standards compliance verified for all procedures

Guidelines

• Never issue a blood product without two-identifier patient verification at both the testing and release stages
• Treat all Kidd system antibodies with heightened vigilance — anti-Jka and anti-Jkb are notorious for evanescent titers and causing delayed hemolytic transfusion reactions
• For patients on anti-CD38 therapy (daratumumab), use DTT-treated screening cells or genotyping to avoid pan-reactivity interference
• Always rule out underlying alloantibodies when a warm autoantibody is present; adsorption studies are mandatory before antigen-negative unit selection
• Maintain a crossmatch-to-transfusion ratio (C:T ratio) below 2.5:1 per AABB best practice to minimize wastage
• Document all emergency uncrossmatched releases and complete full compatibility testing retrospectively within 24 hours
• For prenatal patients, perform antibody titers at defined intervals (every 4 weeks until 24 weeks, then every 2 weeks) for clinically significant antibodies
• Participate in AABB-required proficiency testing and maintain inter-laboratory concordance for antibody identification